Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;57(3):106275.
doi: 10.1016/j.ijantimicag.2020.106275. Epub 2021 Jan 2.

Passive immunization and its rebirth in the era of the COVID-19 pandemic

Charles S Pavia  1 , Gary P Wormser  2
Affiliations
Review

Passive immunization and its rebirth in the era of the COVID-19 pandemic

Charles S Pavia et al. Int J Antimicrob Agents. 2021 Mar.

Abstract

The COVID-19 pandemic, caused by SARS-CoV-2, has led to a rapid search for therapeutic and preventive measures because of the potentially severe course of infection. The antiviral drug, remdesivir, and the anti-inflammatory agent, dexamethasone, have shown beneficial effects. As the current COVID-19 vaccines are not yet fully available to everyone, or they may not be readily and universally accepted, various treatment options are being evaluated and will still be needed under these conditions. One of these treatment options, passive immunization, has shown promise in some studies. Further research is needed to determine the utility of immunotherapy with convalescent plasma or artificially produced monoclonal antibodies for the treatment of symptomatic patients, and potentially for use as post-exposure prophylaxis, at least until more effective drugs are available or safe and effective vaccines are distributed and administered to everyone.

Keywords: COVID-19; Convalescent plasma; Immune globulin; Monoclonal antibodies; Passive immunization; SARS-CoV-2.

PubMed Disclaimer

References

    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 doi: 10.1001/jama.2020.4783.57. - DOI - PMC - PubMed
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 doi: 10.1073/pnas.2004168117. - DOI - PMC - PubMed
    1. Dolman CE. Landmarks and pioneers in the control of diphtheria. Can J Public Health. 1973;64:317–336. - PubMed
    1. The College of Physicians of Philadelphia. Passive Immunization — History of Vaccines. www.historyofvaccines.org. Retrieved on 07-28-2020.
    1. Report Report of the Lancet Special Commission on the relative strengths of diphtheria antitoxic serums. Lancet. 1986;148:182–195. doi: 10.1016/s0140-6736(01)72399-9. PMC 5050965. - DOI

MeSH terms